OneChain Immunotherapeutics

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

OneChain Immunotherapeutics headquartered in Europe, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $174.9M in funding across 16 round(s). With a team of 11-50 employees, OneChain Immunotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - OneChain Immunotherapeutics, raised $7.3M. Discover more about their projects, partnerships, and impact on our platform.